Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. - Wikidata - awgldk - TriplyDB

Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.

Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.

http://www.wikidata.org/entity/Q38041019

about

Overview and recent advances in the treatment of neuroblastoma.Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.Molecular profiling of childhood cancer: Biomarkers and novel therapies Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.Natural compounds for pediatric cancer treatment.Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags.Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance.MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.

P2860

Q30238693-D869906F-C3DC-47FF-889C-FED11D18BE1B Q33419558-821F780A-8EAE-4E3F-B2BF-888B194421CC Q33442162-4A61846B-B25E-4343-A814-AB32D374D7A5 Q35077703-0D9B4E8B-6F9E-4E95-986A-9C7A29C141F2 Q35798960-8316081F-502C-4543-A5AD-D78917FE4237 Q36250783-4C7B56C3-FB2E-42FA-9753-1FA725B16AA9 Q36782374-36459285-3BA8-40FC-9BFF-045AF622F724 Q38663897-6C8D9384-0138-420B-996E-B53C25A6A9D7 Q41394300-DA18B564-4CE8-4C83-83B6-73005882BDCC Q45377423-97410C9A-7A1D-4095-93A5-627EC6DAE13B Q46444617-1A796A26-6B5D-445E-9685-80EAD4DF5524 Q47108370-DFBAFBDC-DE02-4CA1-AD5D-6938E57DD48A

P2860

Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.

http://www.wikidata.org/entity/Q38041019

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Ifosfamide, carboplatin, and e ...... and review of the literature.

@en

type

label

Ifosfamide, carboplatin, and e ...... and review of the literature.

@en

prefLabel

Ifosfamide, carboplatin, and e ...... and review of the literature.

@en

P1433

Q38041019-48F0E811-1BE6-4403-BA4C-28DCDBCD5B43

P1476

Q38041019-73A593A7-BB73-4C78-8806-CAFD9CB63865

P2093

Q38041019-1A43B623-3EC5-4008-BE45-C1C14DE55929

Q38041019-32C8C56F-4C12-45AA-B40B-E22F65367F3E

Q38041019-7F83F322-E305-4504-8D38-BB95A7703ABA

Q38041019-89579203-E960-4F23-B5D7-A4B65548E438

Q38041019-E0A288D1-FDA1-4B79-B275-74C75B895695

P2860

Q38041019-1DABCA23-A750-4D59-B74A-D3FB4FC54C25

Q38041019-1FF7FCD9-313D-47DC-87AE-880F683E74BB

Q38041019-200B75D4-97B9-4357-A7F9-7DC9C0248B3C

Q38041019-2A18868E-84E7-4946-8BFC-125282446F74

Q38041019-2C1EF4E6-1B80-475D-8837-DE8283A9E0AF

Q38041019-37EF6FF4-A7AB-4A89-9743-78AE59E6C9D2

Q38041019-3C999532-AECB-4809-9F16-7D95689EF3C7

Q38041019-4237DF97-9900-40A1-94E7-0D03F3B8B8F8

Q38041019-4E6E56C7-DB88-478F-8D45-2CB2E49A3FFE

Q38041019-620CD9AB-91EE-471F-9506-545D5E1D593F

P304

Q38041019-69EF7239-3876-45C3-8914-C992954B52AD

P31

Q38041019-18D55647-BDFF-42B2-B04A-5BCF5EEC109E

P356

Q38041019-D79E75C9-4B8E-4832-A6FB-557E37C44EF2

P407

Q38041019-7AA7E854-408A-4D64-8AD9-54A827FAF944

P433

Q38041019-181A4291-01F6-43E8-83F6-E0CA4BAEC381

P478

Q38041019-128C6713-C510-41D7-8FA6-B04B0B9ACC10

P50

Q38041019-4E99EFF1-A00D-4D4F-928A-34002A87D4D2

P577

Q38041019-C386A5FE-8459-4EF7-BDC2-AA46FC624F70

P698

Q38041019-490E4F0D-D5ED-4B63-89E2-F4ED694A6C84

P356

P1433

P1476

Ifosfamide, carboplatin, and e ...... and review of the literature.

@en

P2093

Brian H Kushner

http://www.w3.org/2001/XMLSchema#string

Ellen M Basu

http://www.w3.org/2001/XMLSchema#string

Kim Kramer

http://www.w3.org/2001/XMLSchema#string

Nai-Kong V Cheung

http://www.w3.org/2001/XMLSchema#string

Shakeel Modak

http://www.w3.org/2001/XMLSchema#string

P2860

Ifosfamide encephalopathy

Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.

Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial.

Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study

High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.

Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.

Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.

Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.

P304

665-671

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.27783

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Stephen Roberts

P577

2012-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22951749

http://www.w3.org/2001/XMLSchema#string